Related references
Note: Only part of the references are listed.Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection
Jin Wei et al.
CELL (2021)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Changhai Lei et al.
NATURE COMMUNICATIONS (2020)
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Yadi Zhou et al.
CELL DISCOVERY (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Justin Jee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Drug repurposing approach to fight COVID-19
Thakur Uttam Singh et al.
PHARMACOLOGICAL REPORTS (2020)
Human recombinant soluble ACE2 in severe COVID-19
Alexander Zoufaly et al.
LANCET RESPIRATORY MEDICINE (2020)
Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil
Mateus Bringel Oliveira Duarte et al.
CANCERS (2020)
Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells
Sofia Appelberg et al.
EMERGING MICROBES & INFECTIONS (2020)
The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
Alexandra B. Keenan et al.
CELL SYSTEMS (2018)
Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis
Jason Kindrachuk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Share Paper
